Reversal of glibenclamide-induced coronary vasoconstriction by enhanced perfusion pulsatility: possible role for nitric oxide

Cardiovasc Res. 2000 Mar;45(4):1001-9. doi: 10.1016/s0008-6363(99)00414-9.

Abstract

Objectives: ATP-sensitive potassium channels (K+ATP) prominently contribute to basal coronary tone; however, flow reserve during exercise remains unchanged despite channel blockade with glibenclamide (GLI). We hypothesized that increasing perfusion pulsatility, as accompanies exercise, offsets vasoconstriction from K+ATP-channel blockade, and that this effect is blunted by nitric oxide synthase (NOS) inhibition.

Methods: In 31 anaesthetized dogs the left anterior descending artery was blood-perfused by computer-controlled servo-pump, with real-time arterial perfusion pulse pressure (PP) varied from 40 and 100 mm Hg at a constant mean pressure and cardiac workload.

Results: At control PP (40 mm Hg), GLI (50 micrograms/min/kg, i.c.) lowered mean regional coronary flow from 37 +/- 5 to 25 +/- 4 ml/min (P < 0.001). However, this was not observed at 100 mm Hg PP (41 +/- 2 vs. 45 +/- 4). NOS inhibition by NG-monomethyl-L-arginine (L-NMMA) did not alter basal flow at 40 mm Hg PP, but modestly lowered flow (-5%, P < 0.001) at higher PP (100 mm Hg), reducing PP-flow augmentation by -36%, and acetylcholine (ACh) induced flow elevation by -39%. Co-infusion of L-NMMA with GLI resulted in net vasoconstriction at both PP levels (-60% and -40% at 40 and 100 mm Hg PP, respectively). Unlike GLI, vasoconstriction by vasopressin (-43 +/- 3% flow reduction at 40 mm Hg PP) or quinacrine (-23 +/- 7%) was not offset at higher pulsatility (-44 +/- 4 and -23 +/- 6%, respectively). Neither of the latter agents inhibited ACh- or PP-induced flow responses, nor did they modify the effect of L-NMMA on these responses.

Conclusions: Increased coronary flow pulsatility offsets vasoconstriction from K+ATP blockade by likely enhancing NO release. This mechanism may assist exercise-mediated dilation in settings where K+ATP opening is partially compromised.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetylcholine / pharmacology
  • Adenosine / pharmacology
  • Animals
  • Arginine Vasopressin / pharmacology
  • Coronary Circulation / drug effects
  • Coronary Circulation / physiology
  • Coronary Vessels / drug effects*
  • Coronary Vessels / physiology
  • Dogs
  • Enzyme Inhibitors / pharmacology
  • Glyburide / pharmacology*
  • Hypoglycemic Agents / pharmacology*
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Potassium Channel Blockers*
  • Pulsatile Flow
  • Quinacrine / pharmacology
  • Vasoconstrictor Agents / pharmacology*
  • omega-N-Methylarginine / pharmacology

Substances

  • Enzyme Inhibitors
  • Hypoglycemic Agents
  • Potassium Channel Blockers
  • Vasoconstrictor Agents
  • Arginine Vasopressin
  • omega-N-Methylarginine
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Quinacrine
  • Adenosine
  • Acetylcholine
  • Glyburide